IDEXX Laboratories, Inc. $IDXX Stock Position Lifted by Danske Bank A S

Key Points

• Danske Bank A/S raised its IDEXX stake 10.3% in Q4 to 44,061 shares (about $29.8M), and institutional investors now own 87.84% of the company.
• Several analysts have cut price targets and ratings recently (e.g., Stifel to $675, UBS to $640), but the consensus remains a “Moderate Buy” with an average target of $751.
• IDEXX beat Q4 expectations (EPS $3.08 vs. $2.93; revenue $1.09B vs. $1.07B) and set FY2026 guidance of $14.29–$14.80 EPS, even as insiders sold 45,957 shares (~$29.9M) over the past 90 days.

Danske Bank A S lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 44,061 shares of the company's stock after purchasing an additional 4,106 shares during the quarter. Danske Bank A S owned 0.06% of IDEXX Laboratories worth $29,809,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Blalock Williams LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $590,000. Nordea Investment Management AB grew its stake in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company's stock worth $11,283,000 after acquiring an additional 8,845 shares in the last quarter. Beacon Investment Advisory Services Inc. grew its stake in shares of IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company's stock worth $42,588,000 after acquiring an additional 6,710 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of IDEXX Laboratories by 6.8% during the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company's stock worth $38,477,000 after acquiring an additional 3,820 shares in the last quarter. Finally, Mediolanum International Funds Ltd grew its stake in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company's stock worth $24,441,000 after acquiring an additional 4,909 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research note on Tuesday, March 31st. UBS Group cut their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a report on Tuesday. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Finally, BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $751.00.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the business's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares of the company's stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares of the company's stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 45,957 shares of company stock worth $29,862,109. Company insiders own 0.79% of the company's stock.

IDEXX Laboratories Stock Up 1.2%

IDXX opened at $567.46 on Friday. The stock has a fifty day moving average of $589.55 and a 200-day moving average of $651.24. The company has a market capitalization of $45.07 billion, a P/E ratio of 43.42, a P/E/G ratio of 3.45 and a beta of 1.58. IDEXX Laboratories, Inc. has a fifty-two week low of $465.00 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.